• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Optomed

1.71 EUR-3.28 %18/8 11:00
5,674 following

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
-3.28 %
+3.26 %
+14.77 %
-40.63 %
-54.64 %
-55.76 %
-45.19 %
-87.19 %
-62.66 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
36.76M EUR
Turnover
24.68K EUR
P/E (adj.) (26e)
-13.51
EV/EBIT (adj.) (26e)
-9.78
P/B (26e)
1.72
EV/S (26e)
1.81
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
2.00 EUR
Updated
2026-08-17
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 2026-08-17

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
Optomed’s Q2 left me with a slightly schizophrenic feeling. For the first time, profitability shows the concrete change that management has been talking about for years. Revenue was a disappointment, but even though it fell by 8.6 percent, gross profit remained practically unchanged...
yesterday
41
Juha’s new report has been published. There is potential, as long as Aurora AEYE etc. gain more momentum. .. A card worth watching for now Optomed’s investment story is increasingly centered on the growth of Aurora AEYE’s recurring revenue in the United States, which would significantly...
yesterday
by Sheikki
27
A representative from Vivekanandha Educational Institutions visited Finland and met with representatives from Optomed. The discussions covered the use of Optomed’s handheld fundus cameras in diabetic retinopathy screening, as well as collaboration on research, validation, and healthcare...
16 hours ago
by Artoh1
21
AEYE really does still look like small-time tinkering, seeing as they only bring in €400k per quarter. You could easily apply the pizza shop analogy from the Aiforia thread That barely amounts to over €4k in daily revenue. Even that “hundreds of percent” growth from Himberg doesn...
21 hours ago
by Jekkku
20
Hieman hehkuttelua tälle täkäläisittäin tuntemattomalle Galienin tapahtumalle. .. A Fresh Slate of Innovators New York, New York—The Galien Foundation’s roll call of 2026 Prix Galien USA nominees reads like a who’s-who of future healthcare titans. Billed as the Nobel Prize of biopharmaceut...
4 hours ago
by Sheikki
13
You can certainly get this device into a backpack and carry it from point A to point B. Jokes aside. I think this is a good thing, if you evaluate the matter holistically. This certainly signals that there is demand and a market for diabetic retinopathy screening. Now Opto just needs...
yesterday
by Jankkeri
7
Yes, and the door is already open with Aimil over at @india Pretty good openings, and they finally have the product in stock…
16 hours ago
by Mr. Stock
4
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6/11
2026

Interim report Q3'26

18/2
2027

Annual report '26

4/5
2027

Interim report Q1'27

Optomed Q2'26: Apparatförsäljningen drar inte, men de återkommande intäkterna växer
Research2026-08-17 07:00 by
Juha Kinnunen

Optomed Q2'26: Apparatförsäljningen drar inte, men de återkommande intäkterna växer

Optomeds omsättning och vinst i Q2 var betydligt lägre än våra förväntningar, då försäljningen av utrustning fortsatte att vara svag. Positivt i rapporten var den fortsatta tillväxten i försäljningen av Aurora AEYE, minskade kostnader, ett tydligt återhämtat kassaflöde och en rekordhög bruttomarginal.

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Tauriainen

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Leppänen

Optomed

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Wen

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Salonen

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Lee

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Calarco

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Badlani

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Mäkinen

Optomed
Regulatory press release2026-08-14 08:30

Optomed Oyj: Directed share issue without payment to implement Board remuneration

Optomed
Regulatory press release2026-08-14 08:30

Optomed Oyj: Optomed's financial reporting in 2027

Optomed
Regulatory press release2026-08-14 08:00

Optomed Plc: Half-year report January - June 2026

Optomed
Optomed Q2'26 förhandskommentar: Vi förväntar oss en återgång till tillväxt och övervakar kassaflödet
Analyst Comment2026-08-11 07:02 by
Juha Kinnunen

Optomed Q2'26 förhandskommentar: Vi förväntar oss en återgång till tillväxt och övervakar kassaflödet

Vi estimerar att omsättningen har ökat i takt med att försäljningen av utrustning återhämtat sig från en svag inledning på året.

Optomed
Press release2026-06-23 09:43

Redeye: Optomed: Solid device order

Optomed
Optomed fick en order på 1,8 MEUR för utrustning från USA
Analyst Comment2026-06-22 06:58 by
Atte Riikola

Optomed fick en order på 1,8 MEUR för utrustning från USA

Ordern överstiger hela årets intäkter från utrustning och stärker kassan.

Optomed
Regulatory press release2026-06-18 16:30

Inside Information: Optomed receives a large order in the US

Optomed
Press release2026-05-11 15:16

Redeye: Optomed (Q1 Interview): Expecting normalised sales in upcoming quarters

Optomed
Regulatory press release2026-05-08 19:00

Optomed Oyj: Decisions of the Organization Meeting of Optomed's Board of Directors

Optomed
Regulatory press release2026-05-08 13:30

Optomed Oyj: Decisions of the Annual General Meeting

Optomed
Press release2026-05-08 10:10

Redeye: Optomed (Q1 Review): Soft sales weigh on sentiment

Optomed